Mirum Pharmaceuticals, Inc. (MIRM)
93.99
+0.66
(+0.71%)
USD |
NASDAQ |
Nov 13, 16:00
94.05
+0.06
(+0.06%)
After-Hours: 19:59
Mirum Pharmaceuticals Net Income (Quarterly) : -40.77M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -40.77M |
| June 30, 2026 | -67.23M |
| March 31, 2026 | -790.16M |
| December 31, 2025 | -5.73M |
| September 30, 2025 | 2.905M |
| June 30, 2025 | -5.861M |
| March 31, 2025 | -14.68M |
| December 31, 2024 | -23.79M |
| September 30, 2024 | -14.24M |
| June 30, 2024 | -24.64M |
| March 31, 2024 | -25.28M |
| December 31, 2023 | -33.15M |
| September 30, 2023 | -23.59M |
| June 30, 2023 | -74.04M |
| March 31, 2023 | -30.13M |
| December 31, 2022 | -36.43M |
| Date | Value |
|---|---|
| September 30, 2022 | -35.71M |
| June 30, 2022 | -26.92M |
| March 31, 2022 | -36.61M |
| December 31, 2021 | 57.55M |
| September 30, 2021 | -47.11M |
| June 30, 2021 | -43.89M |
| March 31, 2021 | -50.53M |
| December 31, 2020 | -37.20M |
| September 30, 2020 | -21.51M |
| June 30, 2020 | -23.25M |
| March 31, 2020 | -21.31M |
| December 31, 2019 | -17.95M |
| September 30, 2019 | -15.09M |
| June 30, 2019 | -13.56M |
| March 31, 2019 | -5.957M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Incyte Corp. | -784.80M |
| Galectin Therapeutics, Inc. | -9.113M |
| TG Therapeutics, Inc. | 55.46M |
| Ardelyx, Inc. | -0.737M |
| Kodiak Sciences, Inc. | -66.22M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 185.72M |
| Total Expenses (Quarterly) | 226.49M |
| EPS Diluted (Quarterly) | -0.6221 |
| Enterprise Value | 6.499B |
| Gross Profit Margin (Quarterly) | 81.01% |
| Profit Margin (Quarterly) | -21.95% |
| Earnings Yield | -16.19% |
| Normalized Earnings Yield | -6.329 |